Open this publication in new window or tab >>Örebro University, School of Health and Medical Sciences, Örebro University, Sweden. Department of Urology, Faculty of Health and Medical Sciences, Örebro University, Örebro, Sweden.
Örebro University, School of Health and Medical Sciences, Örebro University, Sweden. Örebro University Hospital. Department of Urology, Örebro University Hospital, Örebro, Sweden.
School of Health and Medical Sciences, Örebro University, Örebro, Sweden; Department of Urology, Örebro University Hospital, Örebro, Sweden.
Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston MA, USA; Pathology Unit, Addarii Institute, S Orsola-Malpighi Hospital, Bologna, Italy.
Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston MA, USA; Department of Pathology, Trinity College, Dublin, Ireland.
Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston MA, USA.
Department of Epidemiology, Harvard School of Public Health, Boston MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, USA.
Department of Epidemiology, Harvard School of Public Health, Boston MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston MA, USA.
Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston MA, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, USA; Broad Institute of Harvard and MIT, Cambridge MA, USA; Division of Cancer Studies, King's College London, London, United Kingdom.
Show others...
2015 (English)In: Molecular Cancer Research, ISSN 1541-7786, E-ISSN 1557-3125, Vol. 13, no 10, p. 1431-1440Article in journal (Refereed) Published
Abstract [en]
Assessing the extent of PI3K pathway activity in cancer is vital to predicting sensitivity to PI3K-targeting drugs, but the best biomarker of PI3K pathway activity in archival tumor specimens is unclear. Here, PI3K pathway activation was assessed, in clinical tissue from 1,021 men with prostate cancers, using multiple pathway nodes that include PTEN, phosphorylated AKT (pAKT), phosphorylated ribosomal protein S6 (pS6), and stathmin. Based on these markers, a 9-point score of PI3K activation was created using the combined intensity of the 4-markers and analyzed its association with proliferation (Ki67), apoptosis (TUNEL), and androgen receptor (AR) status, as well as pathologic features and cancer-specific outcomes. In addition, the PI3K activation score was compared with mRNA expression profiling data for a large subset of men. Interestingly, those tumors with higher PI3K activation scores also had higher Gleason grade (P = 0.006), increased AR (r = 0.37; P < 0.001) and Ki67 (r = 0.24; P < 0.001), and decreased TUNEL (r = -0.12; P = 0.003). Although the PI3K activation score was not associated with an increased risk of lethal outcome, a significant interaction between lethal outcome, Gleason and high PI3K score (P = 0.03) was observed. Finally, enrichment of PI3K-specific pathways was found in the mRNA expression patterns differentiating the low and high PI3K activation scores; thus, the 4-marker IHC score of PI3K pathway activity correlates with features of PI3K activation.
Place, publisher, year, edition, pages
American Association for Cancer Research, 2015
National Category
Cancer and Oncology
Research subject
Oncology
Identifiers
urn:nbn:se:oru:diva-47170 (URN)10.1158/1541-7786.MCR-14-0569 (DOI)000365604300008 ()26124442 (PubMedID)2-s2.0-84945245876 (Scopus ID)
Note
Funding Agencies:
Dana-Farber/Harvard Cancer Center Specialized Programs of Research Excellence (SPORE) in Prostate Cancer P50CA090381-08
National Cancer Institute of the NIH UM1CA167552 R01CA141298 R01CA136578 R01CA131945 P01CA89021
Prostate Cancer Foundation Young Investigator awards
2015-12-212015-12-212020-12-01Bibliographically approved